Evidence map›Paper›PMID 41942650›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma using

Chengyang Sun, Jingjing Zhang, Jinling Song, Xuemei Ye, Deying Xie, Jing Li, Heqing Yi

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chengyang SunDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Jingjing ZhangDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Jinling SongDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Xuemei YeDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Deying XieDepartment of Nuclear Medicine, Aksu Prefecture First People's Hospital, Aksu, Xinjiang, 843000, China.
Jing LiDepartment of Nuclear Medicine, Aksu Prefecture First People's Hospital, Aksu, Xinjiang, 843000, China. 1lijing2@163.com.
Heqing YiDepartment of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. yihq@zjcc.org.cn.ORCID 0000-0002-5164-4821

Funding

Zhejiang Province Natural Science Foundation of China LTGY24H180013Zhejiang Provincial "Trailblazer" R&D Program 2026C01043
6 · The paper itself

Abstract

purposeThis study aimed to develop and validate a non-invasive, multimodal radiomics model based on preoperative

methodsThis retrospective study enrolled 291 patients with pathologically confirmed GAC who underwent preoperative

resultsCLDN18.2-positive tumors exhibited a distinct hypometabolic phenotype, characterized by significantly lower SUVmax (P = 0.012) and SUVmean (P < 0.001) compared to negative tumors. The combined multimodal model demonstrated superior discrimination, achieving an AUC of 0.926 (95% CI: 0.891-0.961) in the training cohort and 0.765 (95% CI: 0.665-0.865) in the validation cohort, consistently outperforming single-modality models. SHAP analysis highlighted PET-derived radiomic features and serum CEA as the most influential predictors, confirming the inverse correlation between metabolic activity and CLDN18.2 expression.

conclusionThe developed

Indexed as

AdenocarcinomaClaudinsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRadiomicsStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedRetrospective StudiesClaudinsCLDN18 protein, humanFluorodeoxyglucose F18CLDN18.2Gastric AdenocarcinomaPET/CTRadiomics

Identifiers

PMID41942650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.